Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Proteomics Identification and Validation of Desmocollin-1 and Catechol-O-Methyltransferase as Proteins Associated with Breast Cancer Cell Migration and Metastasis.
|
31617665 |
2019 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both experimental and epidemiological studies suggest the role of COMT in pathogenesis of human breast cancer (BCa).
|
30684530 |
2019 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Individuals with homozygous variant genotypes for GSTP1 or COMT exhibited a higher risk of developing breast cancer than those with wild-type genotypes; however, for CYP1B1, the homozygous variant genotype was associated with a lower risk, and the heterozygous genotype for these 3 genes was not associated with breast cancer development.An individual's risk of breast cancer is only influenced by the specific combination of risk-associated alleles of COMT and GSTP1, despite the protective effects of the homozygous CYP1B1 genotype revealed by univariate analysis.
|
30461653 |
2018 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results indicate that polymorphisms in COMT, CYP17 and CYP19 which are involved in estrogen biosynthesis and metabolism can modulate the potential effects of PFOSA exposure on the development of breast cancer.
|
28157646 |
2017 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The purpose of the present study was to examine the relationships between genetic polymorphisms within Neurotrophic tyrosine kinase receptor 1 (NTRK1), Neurotrophic tyrosine kinase receptor 2 (NTRK2), and catechol-O-methyltransferase ( COMT) and patient symptom burden of QOL, pain, fatigue, anxiety, depression, and sleep disturbance before, during, and after treatment for breast cancer in a subset of participants ( N = 51) in a randomized clinical trial of a novel symptom-management modality for women with breast cancer undergoing chemotherapy.
|
28205449 |
2017 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cross-talk was observed between one-carbon and xenobiotic pathways in breast cancer (RFC 80 G>A, COMT H108L and TYMS 5'-UTR 28 bp tandem repeat) and SLE (CYP1A1 m1, MTRR 66 A>G and GSTT1).
|
25648260 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Participants were healthy postmenopausal women at high risk of breast cancer due to dense breast tissue with differing catechol-O-methyltransferase (COMT) genotypes.
|
26206423 |
2015 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found no statistically significant interactions between any of the PCB groups and CYP1B1 or COMT polymorphisms on the risk of breast cancer.
|
23869875 |
2014 |
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, we tested associations between COMT CpG methylation state and COMT gene expression in breast cancer cell lines.
|
24460628 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In summary, this meta-analysis suggests that the COMT Val158Met polymorphism is not a risk factor for breast cancer development.
|
24146281 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found an independent association of CYP1A1 (Val) and CYP17 (A1) with BC risk.Furthermore, an increased BC risk was observed for women with high serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) and carriers of at least: one CYP1A1 variant Val allele; one variant COMT Met allele; or the common CYP17 A1 allele.
|
24629213 |
2014 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that there may be no overall association between the COMT genotype and breast cancer.
|
22124994 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Effect of catechol-o-methyltransferase-gene (COMT) variants on experimental and acute postoperative pain in 1,000 women undergoing surgery for breast cancer.
|
24343288 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined the potential association of breast cancer risk in Mexican women with the polymorphisms CYP1A1 rs1048943, CYP1B1 rs1056836, COMT rs4680, GSTP1 rs1695, GSTT1 null and GSTM1 null which are involved in estrogen metabolism pathway.
|
23000097 |
2013 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, a study with the larger sample size is needed to further evaluated gene-environment interaction on COMT Val158Met polymorphisms and breast cancer risk.
|
22297695 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Overall, no significant associations between the COMT Val158Met polymorphism and breast cancer risk were found for LL versus HH, HL versus HH, LL versus HL, recessive model LL versus HL+HH, and dominant model LL+HL versus HH.
|
23039364 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to examine the influence of catechol-O-methyltransferase (COMT) Val158Met genotypes on cancer-related fatigue, post-mastectomy pain, and pressure pain hypersensitivity in breast cancer survivors.
|
21898113 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study examined the influence of catechol-O-methyltransferase (COMT) Val158Met genotypes on salivary markers of HPA axis (cortisol), SNS (α-amylase) and immune (IgA) systems, as well as on CRF in breast cancer survivors (BCS).One-hundred BCS participated.
|
21974969 |
2012 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
No association between COMT 1947 G>A (rs4680) or CYP1A1 4889 A>G (rs1048943) and breast cancer was found.
|
20878621 |
2011 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, when this relation was assessed within strata based on estrogen-related factors, a few SNPs (HSD17B1 (rs2010750, rs598126 and rs676387), COMT (rs4680), UGT1A1 (rs8175347) and ESR1 (rs9340799)) seemed to be related to MD in the same direction of their associations with breast cancer risk.
|
22199302 |
2011 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The results suggest that persons treated with chemotherapy for breast cancer who also possess the COMT-Val gene are susceptible to negative effects on their cognitive health.
|
21425136 |
2011 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphisms in CYP17, GSTM1, and catechol-O-methyltransferase (COMT) were not associated with a general increase in breast cancer risk.
|
21129090 |
2011 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among all women and in the postmenopausal subgroup, COMT Met/Met and CYP1B1 Leu/Leu susceptible genotype carriers had higher risk of breast cancer (aORs > 1, OR 95% CIs exclude 1).
|
21438753 |
2011 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The proportion of susceptible genotype (COMT-LL) in breast cancer patients was significantly higher than that in the controls.
|
20591221 |
2010 |
Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
When all 41 studies were pooled into the meta-analysis, there was no evidence for significant association between COMT Val108/158Met polymorphism and breast cancer risk (for Val/Met vs. Val/Val: OR = 0.99, 95% CI = 0.93-1.04; for Met/Met vs. Val/Val: OR = 0.96, 95% CI = 0.88-1.04; for dominant model: OR = 0.97, 95% CI = 0.92-1.03; for recessive model: OR = 0.97, 95% CI = 0.90-1.04).
|
20464630 |
2010 |